AGUETTANT is an independent French pharmaceutical company. AGUETTANT is an integrated specialty pharmaceutical company dedicated to the development and the commercialization of essential hospital medicines mainly in movement disorder & Parkinson disease, critical care, anesthesiology and parenteral micro-nutrients. The company has a strong commercial infrastructure in Europe through its subsidiaries and elsewhere in the world through its international distributors. Our commitment is to guarantee that products we design and manufacture are innovative, safe and easy to use. AGUETTANT '_ s turnover over the past 12 months has reached Û 102 M with more than 20% abroad. Our main project in progress is to build a new R&D and manufacturing unit with the prospect to fuel innovation capabilities and enhance international growth. It is planned to start mid 2015. In 2012 Aguettant has acquired PXÕTherapeutics, a biotech company specializing in custom development and contract manufacturing of therapeutic proteins, monoclonal antibodies and other biological compounds. For more information about AGUETTANT : www.aguettant.com